Kubota Pharmaceutical Holdings Co (TSE:4596) Debt-to-EBITDA : N/A (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4596 Kubota Pharmaceutical Holdings Co Ltd TSE:4596
37 GF Score
Price 円65.00
GF Value 円21.18
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Kubota Pharmaceutical Holdings Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Kubota Pharmaceutical Holdings Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was 円77.69 Mil. Kubota Pharmaceutical Holdings Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was 円0.63 Mil. Kubota Pharmaceutical Holdings Co's annualized EBITDA for the quarter that ended in Jun. 2026 was 円0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Kubota Pharmaceutical Holdings Co's Debt-to-EBITDA or its related term are showing as below:

TSE:4596' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.23   Med: -0.18   Max: -0.02
Current: -0.11

During the past 11 years, the highest Debt-to-EBITDA Ratio of Kubota Pharmaceutical Holdings Co was -0.02. The lowest was -0.23. And the median was -0.18.

TSE:4596's Debt-to-EBITDA is ranked worse than
100% of 303 companies
in the Biotechnology industry
Industry Median: 1.27 vs TSE:4596: -0.11

Kubota Pharmaceutical Holdings Co  (TSE:4596) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Kubota Pharmaceutical Holdings Co Debt-to-EBITDA Related Terms


Kubota Pharmaceutical Holdings Co Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Kubota Pharmaceutical Holdings Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kubota Pharmaceutical Holdings Co Debt-to-EBITDA Chart

Kubota Pharmaceutical Holdings Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.21 -0.18 -0.18 -0.05 -0.19

Kubota Pharmaceutical Holdings Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.14 1.56 -0.13 -0.11 N/A

TSE:4596 vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Kubota Pharmaceutical Holdings Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kubota Pharmaceutical Holdings Co Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kubota Pharmaceutical Holdings Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Kubota Pharmaceutical Holdings Co's Debt-to-EBITDA falls into.


TSE:4596
37GF Score
Kubota Pharmaceutical Holdings Co Ltd TSE:4596
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kubota Pharmaceutical Holdings Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Kubota Pharmaceutical Holdings Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(119.62 + 8.252) / -675.381
=-0.19

Kubota Pharmaceutical Holdings Co's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(77.688 + 0.627) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Kubota Pharmaceutical Holdings Co (TSE:4596) Overvalued in 2026?

Based on GuruFocus' analysis, Kubota Pharmaceutical Holdings Co stock appears to be overvalued. The current stock price of 円65.00 is trading 206.9% above its estimated GF Value™ of 円21.18. GuruFocus considers Kubota Pharmaceutical Holdings Co to be Significantly Overvalued.

Key valuation signals for TSE:4596:

  • Debt-to-EBITDA: N/A
  • GF Value™: 円21.18 vs. price of 円65.00 (206.9% above fair value)
  • GF Score™: 37/100 with 2 warning signs

No single metric tells the full story. See the TSE:4596 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kubota Pharmaceutical Holdings Co Business Description

Address 1-15-37 Minami-Aoyama, Minato-ku, Tokyo, JPN, 107-0062
Kubota Pharmaceutical Holdings Co Ltd is a Japanese company providing portfolio of drugs and devices to preserve and restore millions of people. It identifies and develops therapeutics to treat the opthalmic disorder and operations incidental or related thereto. Its pipeline products include VCM-Emixustat HCI, Lanosterol and Optogenetics.
37GF Score

Get the complete analysis for TSE:4596

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円65.00
Price
円21.18
GF Value